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Purpose or Objective: Conventionally in radiotherapy, a 
large beam forming apparatus is rotated around a stationary 
patient in order to achieve multiple beam angles. However, 
for a number of emerging and existing treatment modalities 
such as proton therapy, heavy ion therapy, MRI guided 
therapy, and synchrotron based therapies, such an approach 
results in prohibitively expensive and complex treatment 
systems. At the same time, much of the world has no access 
whatsoever to even conventional radiation therapy 
treatments. Replacing the gantry rotation with patient 
rotation could lead to much simpler and more cost effective 
treatment units. However, it is often assumed that patient 
acceptance would be a major barrier to widespread use of 
such a system. The purpose of this work was to test this 
assumption by investigating patient tolerance to slow single 
arc rotation. 
 
Material and Methods: The Epley Omniax (Figure 1) is a 
clinically approved medical device conventionally used in 
balance disorder therapy, and can rotate 360 degrees around 
each axis. We used this device to test patient tolerance to 
slow, single arc rotation. Each patient underwent slow, single 
arc rotation in two orientations; sitting and lying. Patients 
were rotated a full 360 degrees in increments of 45 degrees. 
The rotation was paused for 30 seconds at each 45 degree 
increment to simulate beam delivery; in total this simulates 
the delivery of 8 beams. Patients were rotated in both an 
upright (sitting) and lying position in the same session. 
Response was monitored via validated psychometric 
questionnaires for claustrophobia, anxiety, and motion 
sickness. Thus far, 10 of a planned 15 current or former 
cancer patients have been recruited. 
 
 
 
Results: Patient tolerance has been high – 9 out of 10 have 
completed the study without incident, and in general patient 
feedback has been positive. One patient was unable to 
complete the lying rotation, but was still able to complete 
the sitting rotation without issue. No detectible differences 
in anxiety or motion sickness have been observed from either 
sitting or lying rotation. A summary of the patient cohort and 
results thus far is outlined in table 1. Accrual for this study is 
ongoing. 
 
 
Conclusion: Patient rotation could enable much simpler 
treatment for both conventional and advanced treatments – 
however, it is often assumed that patient tolerance to 
rotation would be very low. The results generated thus far 
show that there is at least a cohort of patients who would 
find slow rotation an acceptable therapeutic intervention. 
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Purpose or Objective: Potential severe or lethal toxicity in 
regards to dose escalation of locally-advanced NSCLC patients 
calls for caution. A national quality assurance program was 
conducted over a period of three years in Denmark in order 
to prepare for the heterogeneous FDG-guided dose escalation 
phase 3 trial: NARLAL2. 
 
Material and Methods: A national work group consisting of 
clinical oncologists and medical physicists was established. 
Different workshops were conducted in order to standardise 
1) delineation of organs at risk (OAR) and target, 2) PET 
determination, 3) treatment planning, and 4) IGRT and 
adaptive strategy. In the standard arm, the planning target 
volume (PTV) is prescribed a homogeneous mean dose of 66 
Gy / 33 fractions (fr). For the experimental arm, the mean 
dose is heterogeneously escalated up to 95 Gy / 33 fr for the 
most FDG-PET active part of the primary tumour and 74 Gy / 
33fr for malignant lymph nodes ≥ 4 cc. The escalation is 
always limited in favour of OAR constraints. Dose constraints 
were added to reduce the risk of severe complications. 
Besides the traditional spinal cord, heart and oesophagus 
delineations, thorax wall, aorta, bronchi, trachea, and 
connective tissue (here defined as any remaining voxels in 
mediastinum not included in other OARs or GTV) were 
delineated. A maximum dose of D1cc < 74 Gy for these OARs 
was chosen as safe dose constraints (D1cc < 70 Gy for 
oesophagus). An online catalogue with examples of such 
delineations was created for oncologists. The randomisation 
is performed when both the standard and escalated plans are 
clinically accepted. The two treatment plans, delineations 
and images are prospectively exported to a national 
database, which requires a consistent naming convention for 
delineations within each centre. Endpoint of trial is local 
control and the standard procedure for suspicion of tumour 
recurrence is biopsy. For cases where biopsy is not 
applicable, a central committee has been established to 
evaluate each case. Blood samples are obtained during the 
treatment course for future examination. 
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Results: Dose-volume-histogram data for the standard (solid) 
and escalated (dashed) arms for one patient is presented 
(Figure 1). Centres entering the NARLAL2 trial must 
successfully pass a workshop evaluation on delineation, PET 
determination, treatment planning, and IGRT strategy. 
Additionally, all participating centres should expect to enrol 
≥5 patients/year, use 4D-CT and PET, inverse treatment 
planning, daily online match on soft tissue, and have an 
adaptive treatment strategy. Planning and treatment of the 
initial two patients within each centre are thoroughly 
investigated by a small QA work group consisting of 2 clinical 
oncologists and 4 physicists. Furthermore, every six month 
each centre will be visited by an external oncologist in order 
to ensure that guidelines are still followed throughout the 
duration of the trial. 
 
 
Conclusion: The NARLAL2 trial started patient accrual in 
January 2015 based on this extensive QA work. 
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Purpose or Objective: The purpose of the study was to 
compare a lithium formate dosimetry system with a lithium 
fluoride TL dosimetry system as used in a solid phantom 
developed for remote end-to-end audits of advanced 
radiotherapy treatments, such as IMRT and VMAT. This type 
of inter-dosimeter comparison is of benefit for better 
understanding of advantages and limitations in the use of 
these dosimeters in remote audit programs for radiotherapy.  
 
Material and Methods: A phantom was designed by a 
multinational coordinated research group (Coordinated 
Research Project E24018) with the intention to be used for 
remote end-to-end audits of advanced radiotherapy 
treatment (IMRT and VMAT). The phantom is made of 
polystyrene and includes solid water volumes representing a 
target region (PTV) and an organ at risk (OAR) with two 
measurement points in each. For an audit, the phantom is to 
be loaded with either TLD or EPR dosimeters and sent to 
external clinics to be treated using their local procedure for 
IMRT or VMAT. Dimensions of the active volume of the 
dosimeters used were: 20 mm length and 3 mm diameter for 
TLD, 5 mm height and 4.5 mm diameter for the EPR 
dosimeter. In addition, gafchromic film is used in the audit 
but this is not a subject of the current study. Irradiations 
were performed using VMAT technique and the doses 
determined by the TLDs and EPR dosimeters were compared 
with the TPS calculated doses.  
Results: The absorbed dose determined by the EPR and TL 
dosimeters agreed within 2% with the TPS calculated doses in 
the PTV. In the OAR the discrepancy was larger; the dose 
determined by the EPR system was 3% lower compared to the 
TPS dose while the dose determined by the TLD was 5% 
higher than the TPS dose. The dose difference in the OAR was 
expected to be larger due to the steep dose gradients in this 
region over the dosimeter volume and the phantom 
positioning uncertainties involved.  
 
Conclusion: Both dosimetry systems agree with the TPS 
calculated doses within 2% in the PTV and 5% in the OAR. This 
study shows that both dosimetry systems give results 
acceptable for this application and can be used for remote 
dosimetry audits of IMRT or VMAT. The EPR dosimeters have 
higher resolution due to their smaller size. This is an 
advantage of the EPRs over the TLDs since it is possible to 
resolve dose gradients to a higher extent.  
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Purpose or Objective: Radiotherapy is one of the primary 
treatment options in cancer management. Radiotherapy is 
recognised as one of the safest areas of modern medicine; 
however, when errors occur, the consequences for the 
patient can be significant.  
The rapid development of new technology has significantly 
changed the way in which radiotherapy is planned and 
delivered. Quality and safety programs in radiotherapy have 
been recommended by international bodies, such ESTRO and 
AAPM.  
The purpose of this work is twofold: to report on the long-
term use of an event reporting and learning system in an RT 
department to record and classify events, and to compare a 
restricted access system to an open-access system 
 
Material and Methods: A voluntary web-based safety 
information database for RT was designed for reporting 
individual events in RT and was clinically implemented in 
2011. An event was defined as any occurrence that could 
have, or had, resulted in a deviation in the intended delivery 
of cancer care. The aim of the reporting systemm was to 
encourage process improvement in patient care and safety.  
During the RT process, when something goes wrong and 
results in event, it is initially recorded and reported within 
the RT Department. Initially only the management group 
registered events. From June 2012 all team at RT Department 
(radiation oncologist, radiation therapists, medical physicists, 
nurses, technicians, dosimetrists, medical secretary) can 
directly register events. All events were analyzed inside a 
management group who selected and proposed actions to be 
taken. 
 
Results: We analyzed events from 2011 to 2014 for 6108 
patients who have undergone radiation treatment at our 
hospital. Over this period of time 298 events were reported. 
After the event reporting system became open access (June 
2012), the registered number of events increased significally: 
from 22 in 2011 to 44 in 2012, 120 in 2013 and 112 in 2014. 
The spectrum of reported deviations extendent from minor 
workflow issues to errors in treatment delivery. 
The distribution of the professional who registered the event 
was: 
 
 
 
